Search Results
Bosutinib: a new, safer TKI for frontline CML
Bosutinib in newly diagnosed CML: GI, liver, effusion, and renal safety characterization
Five-year follow-up data from the BFORE trial: bosutinib versus imatinib in CML
5-year update of BFORE: bosutinib vs imatinib in CML
Bosutinib Diet Tips
Bosutinib Versus Ponatinib in R/R CML
Dr. Shapiro Discusses Bosutinib in CML
The BYOND trial: bosutinib shows promise in heavily pre-treated CML patients
Final results of the BFORE trial: bosutinib vs imatinib in CP-CML
Tolerability of bosutinib vs asciminib in heavily pre-treated patients with CML
The challenges associated with long-term TKI use in patients with CML
Andreas Hochhaus: Asciminib vs. Bosutinib in Chronic Myeloid Leukemia
